Loading...
By Amy Orciari Herman
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
Dipeptidyl peptidase-4 (DPP-4) inhibitors — and potentially glucagon-like peptide-1 (GLP-1) receptor agonists — seem associated with increased risk for cholangiocarcinoma, researchers conclude in The BMJ.
Using a U.K. primary care database, the researchers identified nearly 155,000 adults aged 40 or older who were newly prescribed diabetes drugs in 2007 or later. Those with known risk factors for cholangiocarcinoma were excluded.
During a median follow-up of 4.6 years, the incidence of cholangiocarcinoma was 26 per 100,000 person-years of DPP-4 inhibitor use and 19 per 100,000 person-years with GLP-1 receptor agonists, versus 15 per 100,000 with other second- or third-line diabetes drugs. After multivariable adjustment, DPP-4 inhibitors were associated with a 77% increase in risk; GLP-1 receptor agonists conferred a similar risk increase, but it was not statistically significant.
The researchers note that while the absolute risks were low, cholangiocarcinoma has a high fatality rate.
Comment
LINK(S):
The BMJ article (Free)
Background: Recent NEJM Journal Watch General Medicine coverage of cardiovascular effects of one DPP-4 inhibitor (Your NEJM Journal Watch subscription required)